News and Comments

Knowing Better About Gilead and Amgen. The Mess and Miss Following the Storm

  Friday, February 05, 2016

Gilead Sciences More...

Dana-Farber Institute and Array Pharmaceutical Scientists to Work Together

  Tuesday, February 02, 2016

Yes. Dana-Farber Cancer Institute and Array Pharmaceuticals (ARRY) announced an immuno-oncology collaboration with potential applicability in a wide range of cancer indications.    More...

Exelixis has Good News About CABO

  Thursday, January 28, 2016


The Two Pianists. Breakthrough in the Diagnosis and Treatment of Diseases. See also Illumina

  Monday, January 11, 2016

The Evolution of Liquid Biopsy More...

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

  Monday, January 04, 2016

The market looks like angry, probably very angry, as stocks are in a severe selloff mood. There will be many explanations like usual, but it is difficult for us to speculate this time over the correctness of the offered explanations, including the Iran Saudi Arabia crisis, which led to an increase in the oil price whose decrease has caused the previous market’s bad mood.    More...

ARRAY Rallies on Successful NEMO Trial Results of Binetinib on NRAS-Mutant Melanoma

  Wednesday, December 16, 2015

When you do your due diligence, you do not lose your faith in what you believed in giving up to the hype that’s sprayed around you. We were happy today to hear Array BioPharma (ARRY) report that results from the Phase 3 NEMO clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma. The trial met its primary endpoints.  More...

Halozyme PEGPH20 Improves the Efficacy of Halavan In Triple Negative Breast Cancer

  Thursday, December 10, 2015

Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, "Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances Efficacy of Eribulin Mesylate (HALAVEN®) in Triple Negative Breast Cancer Xenografts" at the 38th Annual San Antonio Breast Cancer Symposium (SABCS).   More...

XOMA: Good News for the Firm We Love and Hate but We Never Divorce

  Wednesday, December 02, 2015

XOMA Announces License Agreement with Novo Nordisk for XMetA Program in Diabetes  More...

BIOMARIN: What Happened During the FDA Committee Meeting?

  Wednesday, November 25, 2015


Biomarin: The DMD Drug and the FDA Committee Options

  Tuesday, November 24, 2015

Today, the FDA advisory panel will discuss BioMarin (BMRN) product drisapersen for Duchenne muscular dystrophy based on documents released to the committee by the FDA. The FDA said, “The benefit of drisapersen in exon 51 skip amenable patients is inconclusive at this time. Therefore, the benefit-risk assessments were not made.”  More...

Recent Postings



Valeant Pharmaceuticals International (VRX) Prosensa (RNA) OSI (OSIP) Anadys (ANDS) Seattle Genetics (SGEN) Ziofpharm (ZIOP) IDERA (IDRA) Ridaforolimus Theravance (THRX) Trastuzumab-DM1 Alnylam (ALNY) VANDA (VNDA) ACADIA (ACAD) AERIE PHARMACEUTICALS Telaprevir Sarepta (SRPT) Herceptin Merck (MRK) Roche (ROCHE) Rapamune Exelixis (EXEL) SERES THERAPEUTICS (MCRB) MODERNA Zerenex SUNESIS PHARMACEUTICALS (SNSS) C4 Therapeutics Roche (RHHBY) Biogen Idec (BIIB) Sanofi (SNA) Onyx (ONXX) Intrexon (XON) GlaxoSmithKline (GSK) CRISPR Therapeutics (CRSP) Genentech Jazz Pharmaceuticals (JAZZ) ARGOS (ARGS) Bellicum (BLCM) Galena (GALE) Human Longevity (HLI) JOUNCE THERAPEUTICS (JNCE) Ocular Therapeutix (OCUL) ImmunoGen (IMGN) Intermune (ITMN) Anacor (ANAC) Micromet (MITI) Auspex (ASPX) ISIS (ISIS) NEUROCRINE (NBIX) Cytokinetics (CYTK) AstraZeneca (AZN) Amgen (AMGN) Pluristem (PSTI) Bristol-Myers Squibb (BMY) JUNO (JUNO) Alder Biopharmaceuticals (ALDR) Illumina (ILMN) Advaxis (ADXS) ABBVIE (ABBV) Abbott Laboratories (ABT) OncoCyte (OCX) ARCA (ABIO) Intercept (ICPT) Elan (ELN) Xoma (XOMA) REGULUS (RGLS) Vertex (VRTX) Spike Therapeutics (ONCE) AGOS (ARGS) Sangamo (SGMO) BIOMARIN (BMRN) Vitae Pharmaceuticals (VTAE) Ariad (ARIA) CompuGen (CGEN) HALOZYME (HALO) Sanofi-Aventis (SAN) PORTOLA (PTLA) Sequenom (SQNM) Ionis (IONS) Prolor Biotech (PBTH) KERYX (KERX) RenenxBio (RGNX) Human Genome Sciences (HGSI) LEXICON (LXRX) Agenus (AGEN) CEMPRA (CEMP) Velcade (bortezomib) Array Pharmaceuticals (ARRY) Editas (EDIT) Gilead (GILD) ZALTRAP™ PTC Therapeutics (PTCT) Biocryst (BCRX) galapagos (GLPG) NOVOCURE (NVCR) Regeneron (REGN) NANTKWEST (NK) NEKTAR (NKTR)) Idenix (IDIX) ADVENTRIX (ANX) Agenus (AGEN Theravance Bio Pharma (TBPH) Benlysta (belimumab) Dynavax (DVAX) Mirati Therapeutics (MRTX) Incyte (INCY) Inovio (INO) INNOVIVA (INVA) Global Cell Therapeutics (GBT) Adaptimmune (ADAP) Multiple Myeloma Endometrial Cancer Dendreon (DNDN) SYNTA (SNTA) GUARDIAN HEALTH Revlimid (lenolidamide) Sanofi (SNY) Tysabri TOKAI (TKAOI) Aimmune Therapeutics (AIMT) KITE (KITE)